GINZA NOA CLINIC
Tokyo, Japan International Patient Support
Contact Us

What Are iPS Cells?

iPS cells are induced pluripotent stem cells: specialized body cells that scientists reprogram into stem cells capable of making almost any cell type in the body. They can multiply in culture and be guided toward cells such as nerve or heart cells. Unlike embryonic stem cells, they can be made without using an embryo Faq_ips.

What the Name Means

Induced means the stem-cell state is produced through laboratory reprogramming. Pluripotent describes the ability to develop into the many cell types of the body. Stem cells can renew themselves while remaining unspecialized. The abbreviation iPSC refers to the same type of cell Faq_ips.

What Are iPS Cells?

An iPS cell is not an embryo, a finished organ, or a ready-to-use treatment. Making a useful specialized cell from it is a separate step, called differentiation Faq_ips.

How iPS Cells Are Made

Researchers introduce reprogramming factors into specialized body cells and grow the resulting colonies in a laboratory. In the original 2006 mouse study, Shinya Yamanaka’s team used four factors: Oct3/4, Sox2, Klf4, and c-Myc. The starting cells were fibroblasts, a type of connective-tissue cell 16904174.

Human iPS cells followed in 2007. One early study used OCT4, SOX2, NANOG, and LIN28, showing that the original four-factor combination is not the only route to reprogramming 18029452. Later methods were developed to avoid inserting the reprogramming factors into the cells’ chromosomes Faq_ips.

Researchers then assess whether a line has the expected stem-cell properties and can produce specialized cells. Reprogramming and differentiation are different jobs: first make the flexible starting material, then guide it toward the cell type needed for an experiment or cell product Faq_ips.

The 2012 Nobel Prize in Physiology or Medicine recognized John Gurdon and Shinya Yamanaka “for the discovery that mature cells can be reprogrammed to become pluripotent.” The award recognized the discovery, not approval of a treatment Summary.

iPS Cells vs Other Stem Cells

Cell type Where it comes from What it can become
iPS cells Specialized body cells reprogrammed in a laboratory Many cell types across the body’s three developmental germ layers Faq_ips
Embryonic stem cells Cells taken from an early embryo to establish a stem-cell line Similarly broad developmental potential, but a different source Faq_ips
Blood-forming stem cells Bone marrow, circulating blood, or umbilical cord blood Blood cells; these are used in established transplants for selected cancers and blood disorders Stem cell transplant

The distinction matters when someone says only “stem cells.” Evidence for a blood-forming stem-cell transplant is not evidence for an iPS-derived nerve-cell graft. The cell source, final product, disease, and method of delivery must match the claim being assessed.

What iPS Cells Are Used For

Disease modeling: researchers can make iPS cells from a patient’s body cells and turn them into a cell type affected by that person’s condition. This makes it possible to study cells that would otherwise be difficult to obtain, such as brain cells Faq_ips.

Drug research: iPS-derived cells can be used to investigate drug effects and toxicity without giving the test drug to the cell donor. A result in cultured cells does not, by itself, establish that the drug will work safely in patients Faq_ips.

Cell replacement: researchers also develop specialized cells or cell precursors for transplantation. This is different from injecting undifferentiated iPS cells, which can form tumors. Cell products must be assessed for their particular use Faq_ips.

Are iPS Cell Treatments Approved?

It is no longer accurate to describe every iPS-derived treatment as experimental. Japan’s PMDA records conditional, time-limited approval on March 6, 2026 for the following two products. These are defined products for defined indications, not approval of general “iPS therapy” 000283257.pdf.

Product Cells and delivery Approved indication in Japan
AMCHEPRY (raguneprocel) Donor iPS-derived dopaminergic neuronal progenitor cells transplanted into the brain’s putamen by stereotactic surgery Improvement of motor symptoms in Parkinson’s disease when conventional medicines, including levodopa-containing products, provide an inadequate response 000281617.pdf
RiHEART Donor iPS-derived heart-muscle cell sheets transplanted onto the heart surface Severe heart failure associated with ischemic cardiomyopathy that responds inadequately to standard care, including medicines and invasive interventions 000281693.pdf

Both approvals have a seven-year duration and require post-marketing assessment. PMDA states that available information is limited and efficacy must continue to be evaluated and confirmed. Conditional approval is not a guarantee of benefit, a cure, or confirmation that a particular person can obtain treatment 000281617.pdf 000281693.pdf.

Evidence must be matched to the specific disease and procedure. A Japanese product approval does not establish approval in another country or validate unrelated private-clinic services.

A clinical-trial listing documents a study; it is not proof of effectiveness. Likewise, filing a treatment plan in Japan is not the same as obtaining marketing approval for a product. MHLW describes the Safety Act procedures for providing regenerative medicine separately from the product-regulation framework Index.

Risks and Limits

Tumor formation: undifferentiated cells left in a graft can form teratomas. Genetic changes associated with reprogramming are another safety concern. Modern methods can address some early vector-related risks, but they do not remove the need to assess cell identity, differentiation, and residual undifferentiated cells Faq_ips.

Transplantation and immune suppression: the two Japanese products above use donor-derived cells and involve surgery and immunosuppressive treatment. These bring risks beyond the cells themselves. Their review reports discuss adverse events and product-specific precautions; findings for one product cannot be used as a safety estimate for every iPS-derived treatment 000281617.pdf 000281693.pdf.

Limited evidence: the AMCHEPRY review includes an uncontrolled study with seven transplanted patients and observation up to 24 months. The RiHEART review includes an uncontrolled eight-patient study with 52-week observation. These small studies do not establish a reliable general success rate or settle every long-term risk 000281617.pdf 000281693.pdf.

How to Check a Treatment Claim

Suppose a brochure advertises an “iPS infusion for Parkinson’s.” That wording alone does not identify a product or establish that it matches AMCHEPRY: the reviewed product is a neuronal progenitor-cell graft delivered by brain surgery, not a general intravenous infusion 000281617.pdf. This is a document-checking scenario, not a patient case or treatment recommendation.

Before comparing price or travelling, ask for written answers:

  • What is the exact product name, starting cell source, and final cell type?
  • Which disease and stage does the evidence cover, and how are the cells delivered?
  • Is the offer an approved product, treatment within a clinical trial, or a private-clinic service? What official record supports that status?
  • How many people were treated, was there a comparison group, what outcomes were measured, and how long were they followed?
  • What adverse events, immune-suppression requirements, and long-term follow-up apply?
  • What product-specific testing and records address stem cell treatment safety, and who is responsible if complications occur?

These questions help identify missing information; they cannot determine whether a treatment is medically suitable for you. That requires assessment by a qualified clinician using the exact product information and your medical history.

The Bottom Line

iPS cells are reprogrammed body cells with broad developmental potential, not an embryo and not a treatment by themselves. Their value lies in the cells researchers can make from them—for studying disease, testing drugs, and developing specific cell products. When reading a treatment claim, check the final cell product and its evidence, not just the letters “iPS” Faq_ips.

Need help preparing questions for a clinic enquiry?

Start with a general question for the non-clinical patient support team. Do not send full medical records initially. This contact does not confirm access to the iPS-derived products discussed here.

Contact patient support

Sources

  1. Kyoto University, Center for iPS Cell Research and Application. Frequently asked questions about iPS cells. Background information dated January 2021; used here for cell biology and research methods, not current approval status.
  2. Takahashi K, Yamanaka S. Induction of pluripotent stem cells from mouse embryonic and adult fibroblast cultures by defined factors. Cell. 2006;126:663–676.
  3. Yu J et al. Induced pluripotent stem cell lines derived from human somatic cells. Science. 2007;318:1917–1920.
  4. The Nobel Prize in Physiology or Medicine 2012. Prize summary and official citation.
  5. National Cancer Institute. Stem Cell Transplants in Cancer Treatment.
  6. PMDA. List of Approved Regenerative Medical Products, April 2015–July 2026. Entries for RiHEART and AMCHEPRY dated March 6, 2026.
  7. PMDA. AMCHEPRY (raguneprocel): review report and deliberation results, February 2026.
  8. PMDA. RiHEART: review report and deliberation results, February 2026.
  9. Japan Ministry of Health, Labour and Welfare. Regenerative medicine: legal framework and provision procedures.